Cardiovascular was Medtronic’s largest segment in fiscal 2026, bringing in $13.98B of $36.36B (38%).
| Segment | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $11.52B | $11.83B | $12.48B | $13.98B | ||||||||||
| Cardiac & Vascular Group | — | — | — | — | ||||||||||
| Neuroscience | $8.96B | $9.41B | $9.85B | $10.29B | ||||||||||
| Medical Surgical | $7.99B | $8.42B | $8.41B | $8.82B | ||||||||||
| Minimally Invasive Therapies Group | — | — | — | — | ||||||||||
| Restorative Therapies Group | — | — | — | — | ||||||||||
| Diabetes | $2.26B | $2.49B | $2.76B | $3.11B | ||||||||||
| Diabetes Group | — | — | — | — | ||||||||||
| Other | $495.00M | — | — | — | ||||||||||
| Other Operating Segment | — | — | — | — | ||||||||||
| Other Operating Segments | — | $222.00M | $138.00M | $135.00M | ||||||||||
| Other Adjustments | — | — | -$90.00M | $39.00M | ||||||||||
| Total | $31.23B | $32.36B | $33.54B | $36.36B |
Medtronic brought in $36.36B from its six segments in fiscal 2026, the year ended April 24, 2026. That was up 8.4% from $33.54B in fiscal 2025. Cardiovascular was the largest at $13.98B (38.4%), ahead of Neuroscience at $10.29B (28.3%) and Medical Surgical at $8.82B (24.2%). The other three segments brought in $3.29B combined.
Compared with fiscal 2025, Diabetes grew fastest, up 13.0% to $3.11B. Every segment above 2% of revenue grew.
Medtronic began breaking out Other Operating Segments in fiscal 2024 and Other Adjustments in fiscal 2025. Medtronic stopped reporting Other as a separate segment after fiscal 2023, when it brought in $495.00M.
Rest Of World was Medtronic’s largest region in fiscal 2026, bringing in $18.12B of $36.36B (50%).
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $16.37B | $16.56B | $17.17B | $18.10B | ||||||||||
| U.S. Pension Benefits | — | — | — | — | ||||||||||
| Rest Of World | $14.76B | $15.69B | $16.25B | $18.12B | ||||||||||
| Americas | — | — | — | — | ||||||||||
| Emea | — | — | — | — | ||||||||||
| Asia Pacific | — | — | — | — | ||||||||||
| Greater China | — | — | — | — | ||||||||||
| Ireland | $98.00M | $113.00M | $116.00M | $143.00M | ||||||||||
| Total | $31.23B | $32.36B | $33.54B | $36.36B |
Medtronic brought in $36.36B from its three regions in fiscal 2026, the year ended April 24, 2026. That was up 8.4% from $33.54B in fiscal 2025. Rest Of World was the largest at $18.12B (49.8%), ahead of United States at $18.10B (49.8%) and Ireland at $143.00M (0.4%).
Compared with fiscal 2025, Rest Of World grew 11.5% to $18.12B and United States grew 5.4% to $18.10B. From fiscal 2023 to 2026, combined revenue from these regions grew from $31.23B to $36.36B, a compound annual growth rate of 5.2%. Rest Of World's share of the total rose from 47.3% to 49.8%.
Medtronic (MDT) reports its revenue by segment and by geography. In fiscal 2026, Cardiovascular was its largest segment, bringing in $13.98B (38.4% of the total), followed by Neuroscience at $10.29B (28.3%).
Cardiovascular was Medtronic's largest segment in fiscal 2026, bringing in $13.98B, or 38.4% of the $36.36B total across its six segments.
Rest Of World was Medtronic's largest region in fiscal 2026, bringing in $18.12B, or 49.8% of the $36.36B total across its three regions.
Among Medtronic's segments that make up at least 2% of revenue, Diabetes grew fastest in fiscal 2026, up 13.0% from $2.76B to $3.11B.
Every figure comes from Medtronic's annual financial filings, as reported. Each line keeps the name Medtronic gives it, and years follow its fiscal calendar.
Medtronic's revenue by segment goes back to fiscal 2013, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.